Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Momentum Builds For PCSK9 Class, But Proof Of Safety Still Thin

Executive Summary

Amgen’s Phase II program for its PCSK9 inhibitor AMG 145 impresses when it comes to lowering cholesterol. But the studies were only 12 weeks long and the bigger test for monoclonal antibodies like AMG 145 and Sanofi/Regeneron’s rival REGN727 is proof of longer-term safety in bigger trials.


Related Content

Sanofi/Regeneron’s PSCK9 Inhibitor Alirocumab Passes First Phase III Test
Wary Of Surrogates, Payers Seek Outcomes Data For PCSK9 Class
On Amgen’s Agenda: Bring Biologics To Primary Care
Branded Life After Lipitor: Pharma Targets Unmet Needs In Dyslipidemia
Will New Injectables Sell In An Oral, Mainly Generic Cholesterol World?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts